Sutro Biopharma Q2 revenue misses estimates, posts wider loss
STRO•Analyst coverage
The current average analyst rating on the shares is buy, with 13 strong buy or buy ratings, no hold ratings, and 1 sell or strong sell rating.
The average consensus recommendation for the biotechnology and medical research peer group is buy.
Wall Street's median 12-month price target for Sutro Biopharma Inc is $50.00, about 99.7% above its August 11 closing price of $25.04.
Development outlook
Sutro expects to start a Phase 1 trial for STRO-006 in Q3 2026. It also expects a second dual-payload iADC program with Astellas to enter the clinic in H2 2026.
The company said its cash position is expected to support operations into at least Q2 2028.
Quarterly results miss revenue estimates
Sutro Biopharma said second-quarter revenue fell and missed analyst expectations, while the company posted a wider net loss.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Miss | $9.84 mln | $13.05 mln (11 Analysts) |
| Q2 Net Loss | $38.53 mln | ||
